Live Breaking News & Updates on Allon Executive Management

established from big four accounting firm
PHILADELPHIA, PA, May 11, 2021 (GLOBE NEWSWIRE) Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, today announced the appointment of Leanne Kelly as its Chief Financial Officer.
Ms. Kelly is an accomplished financial executive with over 20 years of experience leading private and publicly traded companies across life science, technology and e-Commerce sectors and a foundation in public accounting.
“Following our IPO earlier this year, we have taken thoughtful steps to strengthen our team and ensure we have key people with the right expertise needed to best position the Company for success. Leanne is a great addition to the Vallon executive management team as CFO and her industry experience and professional track record are perfectl ....

Lehigh University , United States , Jenene Thomas , Leanne Kelly , David Baker , Genaera Corporation , Exchange Commission On , Global Financial Reporting At Optinose Inc , Vallon Pharmaceuticals Inc , Iroko Pharmaceuticals , Chief Financial , Chief Executive Officer , Executive Director , Global Financial Reporting , Senior Vice President , Chief Financial Officer , Flower Orthopedics , Business Economics , Annual Report , Exchange Commission , Nasdaq Vlon , Vallon Pharmaceuticals Inc , Jeanne Kelly , Allon Executive Management , Iroko Pharmaceuticals , Genaera Corporation ,